Advancing personalized, tissue-based heart valve reconstruction through digital twin innovation.
AVaTAR MedTech is honored to collaborate with Long Island University and Dassault Systèmes at the Living Heart Conference 2025, an event where science, engineering, and medical innovation converge to shape the future of cardiovascular care.
Participating in a gathering of this caliber represents a significant milestone for AVaTAR MedTech. It reinforces our commitment to advancing a future in which heart valve reconstruction is tissue-based, fully personalized, and capable of adapting to each patient’s anatomy and physiology.
Our long-term vision is clear: AVaTAR MedTech aims to lead the future of personalized cardiac care by creating autologous, patient-specific heart valves that grow with pediatric patients and function durably throughout adulthood. By leveraging advanced digital twin technologies, we design precise virtual replicas of each patient to optimize valve reconstruction and guide individualized treatment strategies.
At the core of this vision is a simple yet transformative goal: a patient enters the operating room with valve disease and leaves with a durable, personalized valve, crafted from their own tissue or next-generation biomaterials. This approach is designed to evolve beyond aortic valve repair toward broader solutions for valvular disease and structural heart defects.
To bring this vision to life, AVaTAR MedTech is developing next-generation digital twins capable of replicating patient anatomy, simulating diverse physiological scenarios, and enabling highly personalized valve geometries. These innovations aim to reduce complications, lower healthcare costs, and move closer to a once-in-a-lifetime solution for patients.
Partnering with Long Island University and leveraging Dassault Systèmes’ advanced simulation technologies strengthens this journey, aligning clinical innovation with engineering excellence and digital transformation.
